Hematopoietic Stem Cell TransplantationTransplantation, HomologousTransplantation ConditioningGraft vs Host DiseaseTransplantation, AutologousHematologic NeoplasmsBone Marrow TransplantationStem Cell TransplantationMyeloablative AgonistsLiver TransplantationTransplantation ChimeraTissue DonorsWhole-Body IrradiationPeripheral Blood Stem Cell TransplantationGraft SurvivalUnrelated DonorsHistocompatibility TestingTreatment OutcomeKidney TransplantationGraft vs Tumor EffectHistocompatibilityCord Blood Stem Cell TransplantationVidarabineRecurrenceImmunosuppressive AgentsBusulfanRetrospective StudiesGraft RejectionGraft vs Leukemia EffectLeukemiaTransplantation ImmunologyHematopoietic Stem CellsRemission InductionLeukemia, Myeloid, AcuteSurvival AnalysisHeart TransplantationSiblingsSurvival RateHLA AntigensCell TransplantationLung TransplantationTransplantation, IsogeneicDisease-Free SurvivalMultiple MyelomaMyelodysplastic SyndromesTransplantationChimerismTime FactorsPrecursor Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseCyclosporineHematopoietic Stem Cell MobilizationImmunosuppressionDonor SelectionAllograftsOrgan TransplantationCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte TransfusionIslets of Langerhans TransplantationFollow-Up StudiesLymphocyte DepletionT-LymphocytesAntigens, CD34Living DonorsHematologic DiseasesHepatic Veno-Occlusive DiseasePancreas TransplantationLymphoma, Non-HodgkinSalvage TherapyBone Marrow CellsCyclophosphamideCytomegalovirus InfectionsMycophenolic AcidHematopoiesisMelphalanGranulocyte Colony-Stimulating FactorRisk FactorsDirected Tissue DonationAntilymphocyte SerumLeukemia, MyeloidAnemia, AplasticAntineoplastic Combined Chemotherapy ProtocolsSurvivorsBlood Component RemovalNeoplasm, ResidualFetal BloodMice, Inbred C57BLMinor Histocompatibility AntigensPrognosisChronic DiseaseLymphomaTransplantation ToleranceHodgkin DiseaseTacrolimusMesenchymal Stem Cell TransplantationTransplantation, HeterotopicAntineoplastic AgentsBlood CellsLeukapheresis